SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
TipRanks (Fri, 19-Apr 8:42 AM ET)
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga (Fri, 19-Apr 7:58 AM ET)
FYBR, BCRX and SABR are among after hour movers
Seeking Alpha News (Thu, 18-Apr 4:56 PM ET)
TipRanks (Thu, 18-Apr 7:10 AM ET)
SAGE Therapeutics: Hold Rating Reiterated Amid Clinical Trial Setbacks and Uncertainties
TipRanks (Thu, 18-Apr 5:25 AM ET)
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
Benzinga (Wed, 17-Apr 2:34 PM ET)
Benzinga (Wed, 17-Apr 1:36 PM ET)
SINT, ATNF and RETO among mid-day movers
Seeking Alpha News (Wed, 17-Apr 12:53 PM ET)
TipRanks (Wed, 17-Apr 11:30 AM ET)
BofA downgrades Sage to underperform, cites failed Parkinson's study
Seeking Alpha News (Wed, 17-Apr 11:14 AM ET)
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Sage Therapeutics trades on the NASDAQ stock market under the symbol SAGE.
As of April 19, 2024, SAGE stock price climbed to $13.33 with 1,183,252 million shares trading.
SAGE has a beta of 1.77, meaning it tends to be more sensitive to market movements. SAGE has a correlation of 0.07 to the broad based SPY ETF.
SAGE has a market cap of $801.22 million. This is considered a Small Cap stock.
Last quarter Sage Therapeutics reported $78 million in Revenue and -$.55 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.73.
In the last 3 years, SAGE stock traded as high as $80.87 and as low as $10.92.
The top ETF exchange traded funds that SAGE belongs to (by Net Assets): XBI, VTI, VB, IWM, VXF.
SAGE has underperformed the market in the last year with a price return of -72.2% while the SPY ETF gained +21.2%. SAGE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.8% and -19.6%, respectively, while the SPY returned +4.3% and -3.5%, respectively.
SAGE support price is $12.56 and resistance is $13.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAGE stock will trade within this expected range on the day.